NEWSLETTER SEPT 2022

31 Aug 2022 · Cherie Hartley

IR Department client media highlights

IR Department client media highlights:

Read article
NEWSLETTER SEPT 2022

31 Aug 2022 · Paul Langley

Interview with Peter Devine, CEO of Uniseed

We talk with Peter Devine, CEO of Uniseed, about the current ESG landscape, ethical investing, their recent partnership with UniSuper and his surprising leisure activity.

Read article
NEWSLETTER SEPT 2022

29 Aug 2022 · Paul Langley

XPON CEO Matt Forman discusses Wondaris and how it integrates with Google

XPON's Founder and Group CEO Matt Forman explains the ground-breaking technology behind Wondaris and how it is changing the landscape of digital data recording.

Read article
NEWSLETTER SEPT 2022

29 Aug 2022 · Paul Langley

Race Oncology CSO Dr Daniel Tillett discusses the bright future for Zantrene

We speak with Dr Daniel Tillett, Chief Scientific Officer of Race Oncology, about the potential market and efficacy of their drug, Zantrene, which seems likely to change the cancer treatment landscape...

Read article
NEWSLETTER SEPT 2022

29 Aug 2022 · Paul Langley

Mosquito-borne diseases in Australia - an interview with Dr David Foster, CEO of Island Pharmaceuticals

We speak with Dr David Foster, CEO & Managing Director of Island Pharmaceuticals, about the current mosquito-borne diseases landscape in Australia. With recent outbreaks of dengue fever and Japane...

Read article
NEWSLETTER SEPT 2022

29 Aug 2022 · Paul Langley

Kazia Therapeutics CEO Dr James Garner talks with SmallCaps about what's on the horizon

Kazia Therapeutics (ASX: KZA) CEO James Garner joins Small Caps to discuss the company’s ongoing development of its lead drug paxalisib, which recently generated positive interim data in a phase one…

Read article
NEWSLETTER SEPT 2022

29 Aug 2022 · Paul Langley

Interview with Assoc.Prof. Mathias Francois of Gertrude Biomedical

We talk to Associate Professor Mathias Francois of Gertrude Biomedical, world-leaders in small molecular inhibitors to SOX18, a unique drug target with significant commercial and clinical potential

Read article
NEWSLETTER SEPT 2022

29 Aug 2022 · Paul Langley

HaemaLogiX's Tertia Dex explains the KappaMab antibody

HaemaLogix's Chief Manufacturing and Development Officer, Tertia Dex, explains the fascinating process to manufacture KappaMab, a highly-targeted antibody designed to treat mutliple myeloma.

Read article
NEWSLETTER SEPT 2022

04 Jul 2022 · Cherie Hartley

Podcast - IR Department talks with AdAlta CEO & MD, Dr Tim Oldham

Interview with AdAlta’s CEO & Managing Director Dr Tim Oldham

Read article